Targeting the mTOR pathway using deforolimus in cancer therapy

By Mahalingam Devalingam   Sankhala Kamalesh   Mita Alain   Giles Francis J   Mita Monica M  

Future Oncology, Vol. 5, Iss. 3, 2009-04 ,pp. : 291-303

Future Medicine

Access to resources Recommend Favorite

Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 7, 2013-09 ,pp. : 1032-1038

Bentham Science Publishers

Access to resources Recommend Favorite

Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk

By Shu Xiang   Lin Jie   Wood Christopher G.   Tannir Nizar M.   Wu Xifeng  

Journal of the National Cancer Institute, Vol. 105, Iss. 6, 2013-03 ,pp. : 424-432

Oxford University Press

Access to resources Recommend Favorite

Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors

By Roca Sophie   Quivy Amandine   Gross-Goupil Marine   Bernhard Jean-Christophe   De Clermont Henri   Ravaud Alain  

Acta Oncologica, Vol. 50, Iss. 7, 2011-10 ,pp. : 1135-1136

Informa Healthcare

Access to resources Recommend Favorite

Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer

By                

International Journal of Oncology, Vol. 45, Iss. 2, 2014-01 ,pp. : 567-574

Spandidos Publications

Access to resources Recommend Favorite